Experience with infliximab in the treatment of active rheumatoid arthritis and spondyloarthropathy;Erfaringer med infliximab til behandling af aktiv reumatoid artrit og spondylartropati

Ugeskrift for Laeger

Volumn 165, Issue 48, 2003, Pages 4646-4649

  Dahlin, Jan ^b   Sørensen, Søren Freiesleben ^a  

^a BISPEBJERG HOSPITAL   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB;

ACNE; ARTICLE; CLINICAL ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; HUMAN; IMMUNOGENICITY; INFLAMMATION; PUSTULE; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SAPHO SYNDROME; SPONDYLOARTHROPATHY; SYNOVITIS; TREATMENT PLANNING;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; HUMANS; METHOTREXATE; MIDDLE AGED; SPONDYLARTHROPATHIES; TREATMENT OUTCOME;

EID: 1642431678     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Elliott MJ, Maini RN, Feldmann M et al, Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
2. Lipsky PE, van der Heijde DM, St. Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
3. Braun J, Brandt J, Listing J et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93.
4. Gorman JD, Sack KE and Davis SC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α. N Engl J Med 2002;346:1349-56.
5. Arnett FC, Edworthy SM, Block DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis, Arthritis Rheum 1988;31:315-24.
6. Calin A, Garrett S, Whitelock H et al, A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath ankylosing spondylitis functional index. J Rheumatol 1994;21:2281-5.
7. Jenkinson TR, Mallorie PA, Whitelock HC et al. Defining spinal mobility in ankylosing spondylitis (AS). J Rheumatol 1994;21:1694-8.
8. Keane J, Gerishon S, Robert P et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001;15:1098-104.
9. St.Clair EW, Wagner CL, Fasanmade AA et al. The Relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis. Arthritis Rheum 2002;46:1451-9.
10. Baert F, Noman M, Vermeire S et al. Influence of immunogenicity on the long term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:2155-6.